Pre-eclampsia Research

World Pre-Eclampsia Day Research

NEW: APEC Research Portal

One of the key roles of APEC is to be the patient voice in world class research. We have launched a research portal so researchers who need APEC and patients to get involved can quickly ask for our support and provide us with all the information we need to quickly act to help.

The WILL Trial

The WILL Trial

The WILL trial aims to investigate the clinical effectiveness and cost-consequences of planned early term delivery at 38+0 to 38+3 weeks’ gestation, compared with expectant care at term until at least 40+0 weeks’ gestation, in pregnant women with chronic or gestational hypertension that develops by 37+6 weeks’ gestation.

PARROT-2 Follow on study assesses impact of PlGF tests

Researchers at Kings College London are in the process of conducting a follow on study to PARROT, PARROT-2. PlGF-based testing has been demonstrated to be useful in ruling out a diagnosis of pre-eclampsia.

PLGF based tests in suspected pre-eclampsia

The use of PLGF based tests in suspected pre-eclampsia

Placental growth factor (PlGF) is a protein involved in placental angiogenesis (the development of new blood vessels). In pre-eclampsia, levels of PlGF can be abnormally low.

Pre-eclampsia Information and Support

Placental growth factor testing

Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial.

Reducing maternal deaths from hypertensive disorders

Reducing maternal deaths from hypertensive disorders

Confidential inquiries into maternal deaths in the UK were established in 1952 and have aimed to report on every pregnancy related death since then.

PHOENIX trial

The PHOENIX trial is a non-masked, randomised controlled trial, comparing planned early delivery with usual care in women with pre-eclampsia between 34+0 and 36+6 weeks’ gestation.

Latest research news

February 25, 2021

New pre-eclampsia definition better identifies women and babies at risk

A diagnosis of pre-eclampsia identifies women and babies who could benefit from close follow-up, medication (including that to lower blood pressure), and/or earlier birth. In 2019, […]
February 11, 2021

New statement from APEC Chair of Trustees Prof Andy Shennan OBE on antenatal care following COVID-19 pandemic

APEC are making the following statement regarding antenatal care and pre-eclampsia risk following the COVID19 pandemic. Pre-eclampsia • 1 in 30 women will develop pre-eclampsia during […]
January 18, 2021
MBRRACE report 2020 Infographic

MBRRACE Report 2020 now published

Each year the MBRRACE report ” Saving Lives, Improving Mothers’ Care”   looks at maternal mortality in the previous trimester. It is extremely important in the UK […]
November 30, 2020

The WILL Trial – an update

The WILL trial aims to investigate the clinical effectiveness and cost-consequences of planned early term delivery at 38+0 to 38+3 weeks’ gestation, compared with expectant care at term […]
November 26, 2020

Let’s Talk Aspirin – new survey launched for midwives

Low dose aspirin is now widely prescribed to women at risk of pre-eclampsia to reduce their risk of developing the disease. However, we know that some […]
September 29, 2020

Annual Expert Meeting 2020

Speakers included Kemi Badenoch MP and MBRRACE’s Prof Marian Knight. This year like so many other conferences and large meetings the annual expert meeting was held […]

Cradle VSA Blood Pressure Monitor

Find out more about the world’s first medical device to detect shock and high blood pressure in pregnant women that could cut maternal deaths in developing countries by up to 25%, saving more than 70,000 lives a year.